Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
Yuan-Kai ShiJianhua ChenHelong ZhangZhihong ZhangYiping ZhangZhehai WangShucai ZhangJian ZhaoChunling LiuXiuwen WangYanqiu ZhaoChanglu HuLei YangXuezhi HaoLin WangYunpeng LiuYan YuJun ZhaoMengzhao WangLiangming ZhangSanyuan SunYanping HuKangsheng GuXiaosheng HangJinlu ShanYu ZhangBangxian TanWeihua YangRunxiang YangMeimei SiHuaize GengHui LiXiaoyan KangPublished in: BMC medicine (2023)
Center for Drug Evaluation of National Medical Products Administration of China: CTR20190789, registered on April 28, 2019; ClinicalTrials.gov: NCT04641754, registered on November 24, 2020.
Keyphrases
- phase ii study
- advanced non small cell lung cancer
- open label
- locally advanced
- single cell
- healthcare
- cell therapy
- quality improvement
- placebo controlled
- double blind
- clinical trial
- squamous cell carcinoma
- randomized controlled trial
- radiation therapy
- epidermal growth factor receptor
- mesenchymal stem cells
- stem cells